Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
109,628,845
-
Total 13F shares
-
33,518
-
Share change
-
-1,135,110
-
Total reported value
-
$493,385
-
Price per share
-
$14.72
-
Number of holders
-
2
-
Value change
-
-$16,708,819
-
Number of sells
-
2
Institutional Holders of Amylyx Pharmaceuticals, Inc. - Common Stock (AMLX) as of Q4 2023
As of 31 Dec 2023,
Amylyx Pharmaceuticals, Inc. - Common Stock (AMLX) was held by
2 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
33,518 shares.
The largest 10 holders included
VANGUARD GROUP INC, BlackRock Inc., VIKING GLOBAL INVESTORS LP, MORGAN STANLEY, Point72 Asset Management, L.P., Stonepine Capital Management, LLC, MILLENNIUM MANAGEMENT LLC, CITADEL ADVISORS LLC, PERCEPTIVE ADVISORS LLC, and STATE STREET CORP.
This page lists
177
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.